VVVictoriya P. Vladimirova

Victoriya P. Vladimirova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Victoriya P. Vladimirova has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases

    by S A Gronskaia, Zh E Belaya, L Ya Rozhinskaya, G A Melnichenko, T A Dubovitskaya, E O Mamedova, S S Rodionova, Yu V Buklemishev, E A Pigarova, M V Degtyarev, et al.

    Introduction: Tumor-induced osteomalacia is an acquired rare disease manifested by hypophosphatemic osteomalacia due to excessive secretion of fibroblast growth factor 23 (FGF23). FGF 23 is a non-classical hormone secreted by bone tissue (osteocytes) and regulates phosphorus metabolism.The aim of this work is to present clinical experience in the diagnosis, treatment and rehabilitation of patients with tumor-induced osteomalacia.Materials and methods: 40 patients with clinically-confirmed tumor-induced osteomalacia were included in the study, 34 of whom had the tumor localized, 27 underwent surgical treatment and 21 achieved stable remission.Results: The median age was 48 [41; 63] years, 43% were men, the time left from the the onset of the disease was 8 [4; 10] years. Biochemical findings were hypophosphatemia 0.47 [0.4; 0.53] mmol/l, a decrease in the tubular reabsorption phosphate 62 [52; 67]%, and an increase in alkaline phosphatase of 183 [112; 294] units/l. At the time of diagnosis, 100% had multiple pathological fractures, only 10% could move independently, and 77.5% classified the pain as unbearable (8–10 points according to the 10-point pain syndrome scale ). Among the methods used to detect tumors, the most sensitive were scintigraphy with tectrotide with SPECT/CT 71.4% (20/28) and MRI 90% (18/20). In 35% of cases, the tumor was localized in soft tissues and in 65% in bone tissue; The tumor was most often detected in the lower extremities, followed by the head in frequency of localization. 18 patients currently have no remission and they receive conservative treatment (phosphorus and alfacalcidol n=15 and burosumab n=3). In case of achieving remission (n=21), regression of clinical symptoms and restoration of bone and muscle mass was observed. Extensive excision of the tumor without prior biopsy resulted in the best percentage of remission — 87%.Conclusion: Tumor-induced osteomalacia is characterized by severe damage to bone and muscle tissue with the development of multiple fractures, muscle weakness and severe pain syndrome. In laboratory diagnostics, attention should be paid to hypophosphatemia, a decrease in the tubular reabsorption phosphate index and increased alkaline phosphatase. The use of functional diagnostic methods with a labeled somatostatin analogue to the subtype 2 receptor and MRI with contrast enhancement are the most accurate methods of topical diagnostics. In case of localization of the tumor, a wide excision without a preliminary biopsy is recommended.


  • Open Access

    Olfactory function and olfactory bulbs in patients with Kallmann syndrome

    by K. D. Kokoreva, I. S. Chugunov, V. P. Vladimirova, T. E. Ivannikova, V. P. Bogdanov, O. B. Bezlepkina

    BACKGROUND: The majority of Kallmann patients have anosmia or hyposmia. This is how the disease is diagnosed. Some of them don’t have such complaints but olfactory dysfunction is diagnosed via olfactometry. Nowadays there is the lack of information about correlation between olfactometry results and subjective complaints. Correlation between olfactory bulbs size and olfactory dysfunction has been little studied.AIM: To explore olfactory bulb size and olfactory function in patients with congenital isolated hypogonadotropic hypogonadism. To correlate olfactory bulb sizes and smell test scores.MATERIALS AND METHODS: Single-centre comparative study. 34 patients were included. The main group consisted of 19 patients with hypogonadotropic (15 –with Kallmann syndrome, 4 — with normosmic hypogonadism). Olfactory bulbs MRI were provided to all the patients, olfactory test (Sniffin’ Sticks Test) and molecular-genetic studies were provided in all patients with hypogonadism. Control group consisted of 15 patients who were provided with orbits MRI. Olfactory bulbs were evaluated additionally in them.RESULTS: Normal size of olfactory bulbs were only in 1 patient with hypogonadism. Olfactory bulbs height and width were significantly smaller in patients with hypogonadism in comparison with control group (pCONCLUSION: Olfactometry was able to diagnose olfactory dysfunction in 78.5% (i.e. in 15 out of 19 patients with congenital isolated hypogonadotropic hypogonadism. However, anosmia complaints had only 11 out of 19 patients. It is the first results of olfactory bulb sizes in patients with hypogonadotropic hypogonadism in Russia. Uni — or bilateral hypoor aplasia were diagnosed in 94.7% patients with hypogonadism regardless of olfactory dysfunction. Bilateral olfactory bulbs hypoplasia were the most common MRI-finding (36.8%). Unilateral hypoor aplasia was diagnosed in 31.6% patients.


  • Open Access

    Structurall features of the pancreas in patients with type 1 diabetes mellitus

    by M. R. Ragimov, T. V. Nikonova, D. M. Babaeva, V. P. Vladimirova, M. V. Shestakova

    BACKGROUND: Observation of changes in the volume and size of the pancreas has a long history, however, the results of studies are still not unambiguous, the specific causes of changes in pancreatic volume, as well as their consequences, are not clear. According to some data, the decrease of pancreas volume in life expectancy is 35–45% in the population of patients with a long history of type 1 diabetes, and about 20–25% during the first year of the disease. Interestingly, in T1D in 20–45% of cases, the development of exocrine pancreatic insufficiency is noted, one of the manifestations of which is pancreatic atrophy, leading to a decrease in life expectancy.AIM: Assess the volume and size of the pancreas, as well as factors that can influence on their changes.MATERIALS AND METHODS: The study included 78 patients with type 1 diabetes mellitus, the control group consisted of 23 people without previously identified disorders of carbohydrate metabolism, comparable in age and anthropometric parameters with the study group. RESULTS: The volume and dimensions of the pancreas were statistically significantly less in patients with T1D than in the control group. In addition, the influence of the duration of T1D and the age of onset of the disease on these indicators has been proven.CONCLUSION: The volume and size of the pancreas in patients with T1D is less than in healthy individuals. It is necessary to study the effect of these changes on the function of the pancreas.


  • Open Access

    Course of Cushing`s disease and treatment outcomes in correlation with pituitary MRI in children

    by E. A. Yanar, N. V. Makazan, M. A. Kareva, A. V. Vorontsov, V. P. Vladimirova, O. B. Bezlepkina, V. A. Peterkova

    BACKGROUND: Cushing’s disease (CD) is a rare disorder of a persistent cortisol excess caused by ACTH-secreting pituitary tumor (corticotropinoma). Transsphenoidal surgery (TSS) is a treatment of choice for СD, which effectiveness range is from 70 to 90%. Recurrence rate after successful treatment is about 25%. If surgical treatment is unsuccessful or recurrence appear, radiation treatment is the next therapeutic option, which effectiveness range is also 90%, but the hypopituitarism rate as side effect of treatment is higher. Preoperative predictors of remission and recurrence are still unexplored what leads to further investigations.AIM: Analysis of remission and recurrence rates of pediatric CD after successful treatment according to preoperative MRI and therapeutic option.MATERIALS AND METHODS: We conducted a retrospective analysis of 90 pediatric patients with CD who were observed between 1992 and 2020 at the Endocrinology Research Centre.RESULTS: The most common clinical symptoms of CD were weight gain [94%] and growth retardation [72%]. Pituitary tumor was detected on radiological imaging in 53/90 patients [59%], there were no signs of visible adenoma in 37/90 of patients [41%]. 63 of 90 patients underwent TSS (70%), 27 patients underwent radiosurgery (30%). Remission rate after TSS was 71% [45/63], after radiosurgery — 85% [23/27]. There were no significant differences in remission rates after radical treatment according to preoperative MRI results (P=0.21 after TSS and P=0.87 after radiosurgery, х2 analysis). Recurrence after successful treatment was diagnosed in 10 patients. There were no significant differences in time to recurrence according to preoperative MRI results (P=0.055, х2 analysis). Time to recurrence was statistically different after TSS compared to radiosurgery (P=0.007, Kaplan–Meier analysis) and in the group with developed adrenal insufficiency in the early postoperative period (P=0.04, Kaplan–Meier analysis). Analysis of side effect of treatment showed that the frequency of growth hormone and gonadotrophin deficiency was statistically higher after radiosurgery (р< 0.01, Kruskel–Wallis ANOVA test). Diabetes insipidus was diagnosed only after TSS.CONCLUSION: Results of our study didn`t allow to use MRI-results as predictor of effectiveness treatment in pediatric CD. Therapeutic option has an impact on time to recurrence, not on recurrence rates. The frequency of growth hormone and gonadotrophin deficiency was statistically higher after radiosurgery compared to TSS. Further studies are needed to identify predictors of remission and recurrence in CD.


  • Open Access

    Hypophysitis and reversible hypopituitarism developed after COVID-19 infection — a clinical case report

    by N. Yu. Gorbova, В. П. Владимирова, L. Y. Rozhinskaya, Zh. Y. Belaya, Л. Я. Рожинская

    AIM. To present a clinical case of reversible hypopituitarism due to hypophysitis developed after COVID-19 infection.MATERIALS AND METHODS. A patient with residual clinical manifestations of hypopituitarism underwent clinical evaluation at the time of symptoms of hypopituitarism and in follow-up. Morning serum cortisol (171–536 nmol/l) was measured by electrochemiluminescence immunoassay. Morning ACTH (7.2–63.3 pg/ml), prolactin (66–436 mU/l), TSH (0.25–3.5 mIU/L), fT4 (9–19 pmol/l) and fT3 (2.6–5.7 pmol/l) were measured by chemiluminescence immunoassay. Data were analyzed throughout the course of the disease.RESULTS. A 35-year-old female developed clinical symptoms of hypopituitarism two months after recovery from a confirmed COVID-19 infection. Laboratory investigation confirmed hypocorticism, hypothyroidism, hypogonadism and the patient was prescribed appropriate hormonal therapy in January 2021. Four months later the symptoms were alleviated (April 2021) and there were signs of recovery shown by imaging and hormonal: morning serum cortisol 227 nmol/l, morning ACTH 33.96 pg/ml, prolactin 68.3 mU/l, TSH 2.626 mIU/L, fT4 10.75 pmol/l, fT3 3.96 pmol/l. Thyroid hormone was discontinued, but hypogonadism and hypocorticism persisted with estradiol — 51.48 pmol/l, 24h urine cortisol level — 41.8 nmol/day. MRI results showed that the signs of hypophysitis were alleviated in comparison with MRI from January 2021. Full recovery of pituitary axis was reported in October 2021, with recovery of normal menstrual cycle. Furthermore, hormonal profile was likewise normal.CONCLUSION. This report provides evidence of delayed damage to the pituitary gland after infection with the COVID-19, with recovery of its function and structure. To date, the mechanisms of such an impact are not entirely clear; further collection of data on such cases and analysis is required.


  • Open Access

    McCune–Albright syndrome: description of three clinical cases, features of diagnostics and treatment

    by L. Ya. Rozhinskaya, D. G. Sardaeva, N. Y. Kalinchenko, A. M. Chukanova, N. V. Tarbaeva, S. A. Buryakina, V. P. Vladimirova, Z. E. Belaya, G. A. Melnichenko, Л. Я. Рожинская

    McCune Albright syndrome (MAS) is a rare disorder caused by a sporadic postzygotic mutation in the GNAS gene, which encodes the alpha subunit of the Gs signaling protein.Permanent activation of the Gs protein leads to uncontrolled production of intracellular cAMP, and autonomic hyperfunction of target organs. Estimated prevalence of the disease – 1\100000 to 1\1000000. For the first time, MAS syndrome was described in 1936 as a triad of symptoms – fibrous dysplasia of bones (FD), spots on the skin of the color of «coffee with milk» and premature sexual development. However, it is now known, that the phenotype of the disease is much more complex. This is primarily due to the mosaic type of mutation in the GNAS gene, which determines a wide range of clinical manifestations, and presents certain difficulties in the diagnosis of this syndrome. Various endocrinopathies can be manifestations of MAS like an acromegaly, a hyperthyroidism, Cushing’s syndrome, hypophospatemic osteomalacia as well as damage to other organs and systems, namely the pathology of the gastrointestinal tract, hepato-biliary cardiovascular systems. This article presents three late diagnosed clinical cases of MAS in patients with coffee-milk spots and FD, multinodular goiter; in two cases in combination with acromegaly. We have demonstrated the possibilities of drug therapy for acromegaly in MAS, as well as the experience of using bisphosphonate for the treatment of FD.The knowledge of clinical manifestations of the MAS, early diagnostics and possibilities of drug therapy in the management of these patients have the important prognostic value for improving the quality of patient’s life.


  • Open Access

    Clinical and radiological diagnosis of hypophysitis: a review of literature and own data

    by A. V. Vorontsov, D. M. Babaeva, V. P. Vladimirova, T. A. Dubovitskaya, A. O. Gavrilova, Zh. E. Belaya, N. G. Mokryshevа

    Клинико-рентгенологическая диагностика гипофизита: обзор литературы и собственные наблюдения


  • Open Access

    ПРИМЕНЕНИЕ МАГНИТНО-РЕЗОНАНСНОЙ ТОМОГРАФИИ В ДИАГНОСТИКЕ ФИБРОЗНОЙ ДИСПЛАЗИИ ЧЕРЕПА У ДЕТЕЙ С СИНДРОМОМ МАККЬЮНА- ОЛБРАЙТА-БРАЙЦЕВА

    by Д.м. Бабаева, Фгбу «Нмиц Эндокринологии» Минздрава России, Н.в. Маказан, В.п. Владимирова, А.в. Воронцов, М.а. Карева

  • Open Access

    Ovarian adrenal rest tumor in a patient with salt-wasting form of congenital adrenal hyperplasia

    by Natalia V. Molashenko, Diana M. Babaeva, Dmitriy A. Derkatch, Victoriya P. Vladimirova, Tatiana V. Soldatova, Alexander V. Vorontsov, Liliya S. Selivanova, Ekaterina A. Troshina, Elena N. Andreeva, Tatyana A. Ponomareva, et al.

    The article describes the clinical case of diagnosing and choosing the tactics for treating ovarian adrenal rest tumors (OART) in a patient with a salt-wasting form of congenital adrenal hyperplasia (CAH). There are only several clinical cases descriptions of OART in the world literature. At present, the tactics of observation and treatment of the ovarian adrenal rest tumors has not been developed. In each case, individual tactics are chosen. The main predisposing factor to the occurrence of OART is considered to be long periods of decompensation of CAH. ACTH stimulates the hyperplasia and hypertrophy of the residual adrenal tissue in the ovaries and secondary tumors develop. The instrumental methods that allow to diagnose OART include ultrasound, MRI of the pelvic organs, PET with 18FDG. The tactics of treating OART, in contrast to the testicular adrenal rest tumors in men (TART), according to world literature are mainly surgical. Organ-preserving operations were performed, as well as the removal of tumors along with the ovary. Cases of a combination of adenocarcinoma and CAH are also described. Each new case of OART is unique and with the accumulation of international experience, a consensus will be developed.

  • Open Access

    TSH-secreting pituitary adenoma in combination with primary hypothyroidism in the outcome of Hashimoto’s disease: diagnostic difficulties

    by Arina V. Tkachuk, Tatiana A. Grebennikova, Anastasiya M. Lapshina, Victoria P. Vladimirova, Zhanna E. Belaya, Galina A. Melnichenko

    Despite the fact that pituitary adenomas are among the most frequent brain tumours, TSH-secreting pituitary adenomas (thyrotropinomas) are less than 1% of all adenomas. Due to the increase in the free fractions of thyroid hormones at normal or elevated TSH levels, the majority of patients with these pituitary adenomas have a long anamnesis of thyrotoxicosis which requires a differential diagnosis with thyroid pathology (Graves’ disease, toxic adenoma, autonomously functioning thyroid nodules). The diagnosis of the thyrotropinoma is quite challenging for clinicians. This article describes the case of a combination of the thyrotropinoma with primary hypothyroidism as a result of the Hashimoto’s disease. A feature of this article is the absence of a typical clinical picture of thyrotoxicosis in combination with an evaluated level of TSH on the background of constantly increasing substitution therapy for primary hypothyroidism. The picture of space-occupying lesion according to MRI of the brain allowed to suspect hormone-active pituitary adenoma (macroadenoma). As a result of surgical treatment (endonasal transsphenoidal adenomectomy), the level of TSH and free thyroid hormone levels were normalized in the postoperative period. The diagnosis of TSH-secreting pituitary adenoma was confirmed by histological and immunohistochemical analysis of postoperative material.